TransMedics Group
TMDX Mid CapHealthcare · Medical Devices
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
TransMedics Group en bref
TransMedics Group (TMDX) is currently trading at 66,43 € with a market capitalization of 2,3 Md €. The trailing P/E ratio stands at 17.51x, with a forward P/E of 26.68x. The 52-week range spans from 52,18 € to 135,45 €; the current price is 51% below the yearly high. Year-over-year revenue growth stands at +21.2%. The net profit margin stands at 27.04%.
💰 Dividende
TransMedics Group currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
10 analystes évaluent TransMedics Group (TMDX) au consensus : Acheter. L'objectif de cours moyen est de 95,16 €, soit un potentiel de +43.25% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 69,46 € à 123,30 €.
TransMedics Group : la thèse d'investissement en détail
TransMedics Group (TMDX) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 21.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Return on equity of 45.22% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 27.04%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
Le scénario baissier
With a beta near 1.88, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 34.82% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 43.25% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 21.2% sur un an
- Rentable avec une marge nette de 27.04%
- Rentabilité élevée des capitaux propres (45.22% ROE)
- Marge brute élevée de 59.09% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Free cash flow positif
- –Endettement élevé (D/E 174.78)
- –Positions vendeuses élevées (34.82%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to above-average price swings, elevated short interest (34.82%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy TransMedics Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news